Childhood Acute Lymphoblastic Leukemia and Acute Non-Lymphoblastic Leukemia: Differences in Cellular Drug Resistance, with Emphasis on Glucocorticoids — A Pilot Study

  • G. J. L. Kaspers
  • R. Pieters
  • C. H. Van Zantwijk
  • E. Klumper
  • K. Hählen
  • F. C. De Waal
  • E. R. van Wering
  • A. J. P. Veerman
Conference paper
Part of the Haematology and Blood Transfusion / Hämatologie und Bluttransfusion book series (HAEMATOLOGY, volume 36)

Abstract

The improvement in the prognosis of childhood leukemia has been more impressive in acute lymphoblastic leukemia (ALL) than in acute non-lymphoblastic leukemia (ANLL). Using first-line multi-agent chemotherapy about 70% of all children with ALL can be cured [1] compared to 40–50% at best in childhood ANLL [2]. This differences might be caused by a relative resistance of the ANLL cells to the applied cytostatic agents. Therefore, we studied whether differences in cellular resistance to 14 drugs could be detected between untreated ALL and ANLL samples. Special attention was given to glucocorticoids (GC). GC are highly effective in childhood ALL, but largely ineffective in ANLL [3]. However, GC might be of benefit to certain ANLL patients, who are difficult to identify clinically.

Keywords

Leukemia Dexamethasone Glucocorticoid Alkaloid Prednisolone 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Rivera GK, Raimondi SC, Hancock ML, Behm FR, Pui C-H, Abromowitch M, Mirro J Jr, Ochs JS, Look TA, Williams DL, Murphy SB, Dahl GV, Kalwinsky DK, Evans WE, Kun LE, Simone JV, Crist WM (1991) Improved outcome in childhood acute lymphoblastic leukaemia with reinforced early treatment and rotational combination chemotherapy. Lancet 337: 61–66PubMedCrossRefGoogle Scholar
  2. 2.
    Creutzig U, Ritter J, Schellong G (1990) Identification of two risk groups in childhood acute myelogeneous leukemia after therapy intensification in study AML-BFM-83 as compared with study AML-BFM-78. Blood 75: 1932–1940PubMedGoogle Scholar
  3. 3.
    Henderson ES (1969) Treatment of acute leukemia. Semin Hematol 6: 271–319PubMedGoogle Scholar
  4. 4.
    Bosanquet AG (1991) Correlations between therapeutic response of leukaemias and in vitro drug-sensitivity assay. Lancet 337: 711–714PubMedCrossRefGoogle Scholar
  5. 5.
    Pieters R, Huismans DR, Loonen AH, Hählen K, Van Der Does-Van Den Berg A, Van Wering ER, Veerman AJP (1991) Relation of cellular drug resistance to long-term clinical outcome in childhood acute lymphoblastic leukaemia. Lancet 338: 399–403PubMedCrossRefGoogle Scholar
  6. 6.
    Pieters R, Kaspers GJL, Van Wering ER, Huismans DR, Loonen AH, Hählen K, Veerman AJP (1992) In vitro drug resistance in childhood acute lymphoblastic leukemia in relation to age and immunophenotype. Haematol Blood Transf 34: 309–320Google Scholar
  7. 7.
    Veerman AJP, Pieters R (1990) Drug sensitivity assays in leukaemia and lymphoma. Br J Haematol 74: 381–384PubMedCrossRefGoogle Scholar
  8. 8.
    Kaspers GJL, Pieters R, Van Zantwijk CH, De Laat PAJM, De Waal FC, Van Wering ER, Veerman AJP (1991) In vitro drug sensitivity of normal peripheral blood lymphocytes and childhood leukaemic cells from bone marrow and peripheral blood. Br J Cancer 64: 469–474PubMedCrossRefGoogle Scholar
  9. 9.
    Pieters R, Loonen AH, Huismans DR, Broekema GJ, Dirven MWJ, Heyenbrok MW, Hählen K, Veerman AJP (1990) In vitro sensitivity of cells from children with leukemia using the MIT assay with improved culture conditions. Blood 76: 2327–2336PubMedGoogle Scholar
  10. 10.
    Dow LW, Dahl GV, Kalwinsky DK, Mirro J, Nash MB, Roberson PK (1986) Correlation of drug sensitivity in vitro with clinical responses in childhood acute myeloid leukemia. Blood 68: 400–405PubMedGoogle Scholar
  11. 11.
    Smith PJ, Lihou MG (1986) Prediction of remission induction in childhood acute myeloid leukemia. Aust N Z J Med 16: 39–42PubMedCrossRefGoogle Scholar
  12. 12.
    Ho AD, Hunstein W, Ganeshaguru K, Hoffbrand AV, Brandeis WE, Denk B (1982) Therapeutic and prognostic implications of glucocorticoid receptors and terminal deoxynuc1eotidyl transferase in acute leukemia. Leuk Res 6: 1–8PubMedCrossRefGoogle Scholar
  13. 13.
    Weisenthal LM, Dill PL, Finklestein JZ, Duarte TE, Baker JA, Moran EM (1986) Laboratory detection of primary and acquired drug resistance in human lymphatic neoplasms. Cancer Treat Rep 70: 1283–1295PubMedGoogle Scholar
  14. 14.
    Crabtree GR, Smith KA, Munck A (1978) Glucocorticoid receptors and sensitivity of isolated human leukemia and lymphoma cells. Cancer Res 38: 4266–4272Google Scholar
  15. 15.
    Holbrook NJ, Bloomfield CD, Munck A (1983) Analysis of activated and nonactivated cytoplasmic glucocorticoid-receptor complexes from human leukemia cells by rapid DNA-diethyl-aminoethyl minicolumn chromatography. Cancer Res 43: 4478–4482PubMedGoogle Scholar
  16. 16.
    McCaffrey R, Lillquist A, Bell R (1982) Abnormal glucocorticoid receptors in acute leukemia cells. Blood 59: 393–400PubMedGoogle Scholar
  17. 17.
    Thompson EB, Smith JR, Bourgeois S, Harmon JM (1985) Glucocorticoid receptors in human leukemias and related diseases. Klin Wochenschr 63: 689–698PubMedCrossRefGoogle Scholar
  18. 18.
    Pui C-H, Raimondi SC, Head DR, Schell MJ, Rivera GK, Mirro J Jr, Crist WM, Behm FG (1991) Characterization of childhood acute leukemia with multiple myeloid and lymphoid markers at diagnosis and at relapse. Blood 78: 1327–1337PubMedGoogle Scholar
  19. 19.
    Kaspers GJL, Pieters R, Van Zantwijk CH, De Waal FC, Van Wering ER, Veerman AJP (1992) Sensitivity of childhood acute lymphoblastic leukemia cells to prednisolone and dexamethasone assessed by the MTT assay. Haematol Blood Transf 34: 327–331Google Scholar
  20. 20.
    Cline MJ, Rosenbaum E (1968) Prediction of in vivo cytotoxicity of chemotherapeutic agents by their in vitro effect on leukocytes from patients with acute leukemia. Cancer Res 28: 2516–2521PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1994

Authors and Affiliations

  • G. J. L. Kaspers
    • 1
  • R. Pieters
    • 1
  • C. H. Van Zantwijk
    • 1
  • E. Klumper
    • 1
  • K. Hählen
    • 2
    • 3
  • F. C. De Waal
    • 1
    • 3
  • E. R. van Wering
    • 3
  • A. J. P. Veerman
    • 1
    • 3
  1. 1.Department of PediatricsFree University HospitalAmsterdamThe Netherlands
  2. 2.Department of Pediatrics, Division Haematology/OncologySophia Children’s HospitalRotterdamThe Netherlands
  3. 3.Dutch Childhood Leukemia Study GroupThe HagueThe Netherlands

Personalised recommendations